ROLONTIS® (eflapegrastim)

ROLONTIS® (eflapegrastim) is an investigational drug not yet approved by the FDA.


ROLONTIS® (eflapegrastim) is an investigational granulocyte-colony stimulating factor (G-CSF) analog. It comprises two protein components—an analog of G-CSF and an Fc antibody fragment—tethered by a flexible polyethylene-glycol linker.

> To read the latest news about eflapegrastim, or to watch a video on its mechanism, click here.

ROLONTIS® (eflapegrastim) data suggest that the human IgG4-derived Fc fragment of eflapegrastim interacts with a specific Fc receptor called FcRn, which is expressed in endothelial cells and in bone marrow, and is thought to prolong its retention in these tissues.

ROLONTIS® (eflapegrastim) is an investigational drug not yet approved by the FDA.

More About ROLONTIS® (eflapegrastim)

Development Indications

Being evaluated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

Latest News on ROLONTIS® (eflapegrastim)